Increased expression but not sensitivity to Fas/CD95 in glioblastoma cells depleted of mitochondrial DNA.

Bertrand C Liang
Author Information
  1. Bertrand C Liang: Pfenex Inc., San Diego, CA 92121; and Department of Medicine, Division of Human Medical Genetics, University of Vermont College of Medicine, Burlington, VT 05405, USA.

Abstract

Mitochondria and Fas (CD95) play a role in tumorigenicity and apoptosis. In the present study, the functional relationship of mitochondria to Fas in mediating apoptosis was investigated. Glioblastoma cells (DBTRGO5MG, U87) were depleted of mitochondrial DNA (mtDNA) by treatment with ethidium bromide (Rho(-) cells). Compared to Rho(+) cells, Rho(-) cells showed enhanced expression of Fas at the cell surface. Indeed, when Rho(+) cells were treated with mitochondrial respiratory chain complex inhibitors, Fas cell surface expression was noted to increase in a similar fashion to the depletion of mtDNA in both cell lines. However, when cells were evaluated for sensitivity to apoptosis using Fas-engagement, there was no difference between the Rho(+) and Rho(-) cells in either cell line. By contrast, sensitivity to the cytotoxic agent cis-diammine-dichloroplatinum (cisplatin) was markedly increased in the Rho(-) cells, which expressed higher levels of cell surface Fas. Expression of Fas is increased with the depletion of mtDNA and respiratory complex inhibitors. However, this increase in expression does not necessarily translate to an increase in sensitivity to Fas-engagement, although there is an increase in the sensitivity of depleted cells to cytotoxic agents such as cisplatin.

References

  1. Science. 1997 Feb 21;275(5303):1132-6 [PMID: 9027315]
  2. Cell Death Differ. 1998 May;5(5):450-7 [PMID: 10200495]
  3. J Invest Dermatol. 2001 Aug;117(2):333-40 [PMID: 11511312]
  4. Science. 1995 Apr 21;268(5209):411-5 [PMID: 7536343]
  5. Nature. 1999 Feb 4;397(6718):441-6 [PMID: 9989411]
  6. Nat Med. 1996 May;2(5):574-7 [PMID: 8616718]
  7. J Exp Med. 1999 Jan 18;189(2):381-94 [PMID: 9892620]
  8. Science. 1994 Mar 25;263(5154):1759-62 [PMID: 7510905]
  9. Cell. 1997 Nov 28;91(5):627-37 [PMID: 9393856]
  10. J Immunol Methods. 1991 Jun 3;139(2):271-9 [PMID: 1710634]
  11. Cancer Res. 1997 Dec 15;57(24):5571-8 [PMID: 9407969]
  12. Cancer Res. 1997 May 1;57(9):1758-68 [PMID: 9135020]
  13. Oncogene. 1996 Jul 4;13(1):21-9 [PMID: 8700549]
  14. J Immunol. 1994 Feb 15;152(4):1751-5 [PMID: 7509828]
  15. Cancer Res. 1996 May 1;56(9):2033-8 [PMID: 8616847]
  16. Mutat Res. 1998 Feb 26;398(1-2):19-26 [PMID: 9626961]
  17. Nature. 1993 Jan 28;361(6410):365-9 [PMID: 8381212]
  18. EMBO J. 1993 Aug;12(8):3095-104 [PMID: 8344250]
  19. FEBS Lett. 1995 Nov 27;376(1-2):15-8 [PMID: 8521957]
  20. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2205-9 [PMID: 9815616]
  21. Mol Cell Biol. 1999 May;19(5):3842-7 [PMID: 10207107]
  22. Science. 1995 Mar 10;267(5203):1449-56 [PMID: 7533326]
  23. Immunol Today. 1997 Jan;18(1):44-51 [PMID: 9018974]
  24. Cell. 1994 Oct 21;79(2):353-64 [PMID: 7954801]
  25. J Biochem. 1996 Sep;120(3):600-7 [PMID: 8902626]
  26. Arch Dermatol Res. 1996 May;288(5-6):267-9 [PMID: 8738574]
  27. Cancer Res. 1995 Jul 1;55(13):2936-44 [PMID: 7540953]
  28. Exp Cell Res. 1995 Sep;220(1):232-40 [PMID: 7664840]
  29. J Exp Med. 1996 Apr 1;183(4):1533-44 [PMID: 8666911]
  30. J Exp Med. 1995 Aug 1;182(2):367-77 [PMID: 7629499]
  31. Cell Growth Differ. 1997 Nov;8(11):1189-98 [PMID: 9372242]
  32. J Exp Med. 1996 Oct 1;184(4):1331-41 [PMID: 8879205]
  33. Cell Growth Differ. 1997 May;8(5):523-32 [PMID: 9149903]
  34. Nature. 1995 Apr 27;374(6525):814-6 [PMID: 7536895]
  35. Mol Cell Biol. 1999 Sep;19(9):5991-6002 [PMID: 10454546]
  36. Cell Death Differ. 2010 Mar;17(3):551-61 [PMID: 19798106]
  37. J Biol Chem. 2002 Feb 22;277(8):5810-5 [PMID: 11741983]
  38. Cancer Res. 1997 Aug 15;57(16):3331-4 [PMID: 9269989]
  39. Blood. 1995 Feb 1;85(3):757-64 [PMID: 7530506]
  40. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11752-6 [PMID: 7972136]
  41. Methods Enzymol. 1996;264:304-13 [PMID: 8965704]
  42. J Cell Biol. 1995 Jul;130(1):157-67 [PMID: 7790370]
  43. Eur J Immunol. 1995 Dec;25(12):3277-84 [PMID: 8566012]
  44. EMBO J. 1998 Jan 2;17(1):37-49 [PMID: 9427739]
  45. EMBO J. 1998 Mar 16;17(6):1675-87 [PMID: 9501089]
  46. Biochimie. 1990 Feb-Mar;72(2-3):115-21 [PMID: 2165819]
  47. J Exp Med. 1996 Apr 1;183(4):1293-5 [PMID: 8666886]
  48. Nat Med. 1997 Jun;3(6):614-20 [PMID: 9176486]
  49. Nature. 1997 Jul 10;388(6638):190-5 [PMID: 9217161]
  50. Immunol Today. 1995 Jan;16(1):39-43 [PMID: 7533498]
  51. J Clin Invest. 1997 Feb 1;99(3):403-13 [PMID: 9022073]
  52. Pharm Res. 2008 Apr;25(4):740-51 [PMID: 17674158]
  53. Cell Death Differ. 2010 Oct;17(10):1613-23 [PMID: 20395960]
  54. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3759-64 [PMID: 9108051]
  55. Clin Cancer Res. 1998 Mar;4(3):773-81 [PMID: 9533547]
  56. Cancer Res. 1994 Mar 15;54(6):1580-6 [PMID: 7511047]
  57. Cell Death Differ. 1998 Aug;5(8):694-701 [PMID: 10200525]
  58. Science. 1998 Aug 28;281(5381):1309-12 [PMID: 9721092]
  59. FEBS Lett. 1996 Apr 8;384(1):53-7 [PMID: 8797802]
  60. Lab Invest. 1993 Oct;69(4):415-29 [PMID: 7693996]
  61. Exp Cell Res. 2010 Apr 1;316(6):887-99 [PMID: 20026107]
  62. Blood. 1995 Jun 15;85(12):3566-76 [PMID: 7540067]
  63. Int J Cancer. 1994 May 1;57(3):371-7 [PMID: 8168998]
  64. Nature. 1992 Mar 26;356(6367):314-7 [PMID: 1372394]
  65. Cancer Res. 1997 Sep 1;57(17):3823-9 [PMID: 9288794]
  66. Science. 1989 Jul 21;245(4915):301-5 [PMID: 2787530]
  67. Blood. 1997 Aug 1;90(3):935-43 [PMID: 9242521]
  68. J Biol Chem. 1993 May 25;268(15):10932-7 [PMID: 7684370]
  69. Nature. 1995 Apr 27;374(6525):811-3 [PMID: 7723826]
  70. J Cell Biol. 1996 Apr;133(2):335-43 [PMID: 8609166]
  71. J Cell Biol. 1998 Mar 23;140(6):1485-95 [PMID: 9508780]

Word Cloud

Created with Highcharts 10.0.0cellsRhoFascellsensitivity-expressionincreaseapoptosisdepletedmitochondrialmtDNA+surfaceDNArespiratorycomplexinhibitorsdepletionHoweverFas-engagementcytotoxiccisplatinincreasedMitochondriaCD95playroletumorigenicitypresentstudyfunctionalrelationshipmitochondriamediatinginvestigatedGlioblastomaDBTRGO5MGU87treatmentethidiumbromideComparedshowedenhancedIndeedtreatedchainnotedsimilarfashionlinesevaluatedusingdifferenceeitherlinecontrastagentcis-diammine-dichloroplatinummarkedlyexpressedhigherlevelsExpressionnecessarilytranslatealthoughagentsIncreasedFas/CD95glioblastoma

Similar Articles

Cited By